Charles River Laboratories International (NYSE:CRL) Rating Lowered to Neutral at The Goldman Sachs Group
Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by analysts at The Goldman Sachs Group from a “buy” rating to a “neutral” rating in a note issued to investors on Friday, Marketbeat reports. They currently have a $170.00 price objective on the medical research company’s stock, down from their previous price objective […]
More Stories
Harbour Investments Inc. Sells 71 Shares of AppLovin Co. (NASDAQ:APP)
Harbour Investments Inc. lowered its stake in shares of AppLovin Co. (NASDAQ:APP – Free Report) by 45.8% in the fourth...
Signaturefd LLC Sells 4,522 Shares of Smurfit Westrock Ltd (NYSE:SW)
Signaturefd LLC lowered its stake in shares of Smurfit Westrock Ltd (NYSE:SW – Free Report) by 80.7% during the fourth...
JPMorgan Chase & Co. (NYSE:JPM) Shares Acquired by Parallel Advisors LLC
Parallel Advisors LLC lifted its position in JPMorgan Chase & Co. (NYSE:JPM) by 0.9% during the fourth quarter, according to...
Signaturefd LLC Has $18.21 Million Stock Position in JPMorgan Chase & Co. (NYSE:JPM)
Signaturefd LLC increased its stake in JPMorgan Chase & Co. (NYSE:JPM) by 2.8% in the 4th quarter, according to the...
Natixis Advisors LLC Has $1.91 Million Position in CAVA Group, Inc. (NYSE:CAVA)
Natixis Advisors LLC boosted its position in shares of CAVA Group, Inc. (NYSE:CAVA – Free Report) by 54.1% during the...
Cibc World Markets Corp Makes New $355,000 Investment in StepStone Group LP (NASDAQ:STEP)
Cibc World Markets Corp acquired a new stake in shares of StepStone Group LP (NASDAQ:STEP – Free Report) in the...